Page 11 - RxExam's Naplex Theory Book Part 2

www.pharmacyexam.com Krisman

Dose Special Notes

Epoetin beta 2). Epoetin beta methoxy polyethylene glycol (Mircera) is NOT
methoxy indicated for the treatment of anemia due to cancer chemotherapy.
propylene glycol
(Injection)
3). Patients experienced greater risks for death and serious
cardiovascular events when administered erythropoiesis-stimulating
agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs.
11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Individualize dosing to
achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

4). ESAs, including Epoetin beta methoxy polyethylene glycol
(Mircera), shortened overall survival and/or time-to-tumor
progression in clinical studies in patients with advanced breast, head
and neck, lymphoid and non-small cell lung malignancies when dose to
a target hemoglobin of ≥ 12 g/dL.

5). An increased incidence of deep vein thrombosis, serious
cardiovascular events and strokes (especially in chronic renal failure
patients), pure red cell aplasia (PRCA), severe anemia, hypertension
and seizure are reported side effects of Epoetin beta methoxy
polyethylene glycol (Mircera).

B). Colony Stimulating Factors (CSF)

Filgrastim 1. MC: 1). Filgrastim (Neupogen) is a human granulocyte colony-stimulating
(Injection) 5 mcg/kg/day‚ factor (G-CSF) produced by recombinant DNA technology. Filgrastim
given as a single (Neupogen) is produced by Escherichia coli (E coli) bacteria into which
daily injection by the human granulocyte colony-stimulating factor gene has been
SC bolus injection‚ inserted. Colony-stimulating factors are glycoproteins which act on
by short IV infusion hematopoietic cells by binding to specific cell surface receptors and
(15 to 30 minutes)‚ stimulating proliferation‚ differentiation commitment‚ and some end-
or by continuous cell functional activation.
SC or continuous
IV infusion. 2). Filgrastim (Neupogen) is indicated to reduce the duration of
neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile
2. BMT: neutropenia‚ in:
10 mcg/kg/day
given as an IV a). Cancer patients receiving myelosuppressive chemotherapy (MC)
infusion of 4 or 24 b). Patients with acute myeloid leukemia receiving induction or
hours‚ or as a consolidation chemotherapy (AML)
continuous 24- c). Cancer patients receiving bone marrow transplant (BMT)
hour SC infusion. d). Patients undergoing peripheral blood progenitor cell collection and
therapy (PBPC)
e). Patients with congenital‚ cyclic‚ or idiopathic neutropenia.

10